This article explores the ongoing debate about the extent of pelvic lymph node dissection (PLND) during prostatectomy.
While PLND is crucial for staging and prognostic purposes, its therapeutic benefits remain uncertain. The discussion covers the reliability of PLND for staging, the potential impact of advanced imaging techniques like PSMA PET, and the associated risks and morbidity of extended PLND.
The article concludes with a call for more targeted clinical trials to clarify PLND’s role in prostate cancer treatment.
